Skip to main content

Table 2 Diagnostic performance of the AD CSF biomarker panel compared to p-taurel

From: No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis

  AD panel   p-taurel 1–42/p-taurel p-tau181/p-taurel
AD vs. non-AD p-tau181 0.883 0.619$   
1–42/p-tau181 0.860   0.657$  
AD vs. FTLD p-tau181 0.933 0.799$   
1–42/p-tau181 0.920   0.846$  
AD vs. DLB t-tau 0.863 0.706$   
1–42/t-tau 0.855   0.747$  
AD vs. CJD t-tau 0.896 0.978*   
p-tau181/t-tau 1.000    1.000
AD vs. controls t-tau 0.926 0.865   
1–42/t-tau 0.976   0.949  
FTLD vs. controls 1–42 0.679 0.588   
p-tau181/t-tau 0.827    0.695
DLB vs. controls 1–42 0.747 0.717   
1–42/p-tau181 0.739   0.815  
CJD vs. controls t-tau 0.978 1.000   
1–42/t-tau 1.000   1.000  
  1. The third column contains AUC values for the established single markers and biomarker ratios with the highest diagnostic value
  2. Adjacent columns show AUC values of p-taurel and the equivalent ratio using p-taurel
  3. Significant differences between AUC values (DeLong tests, p < 0.05) are marked by an asterisk (*) when diagnostic power is significantly higher with addition of p-taurel, and by a dollar sign ($) when diagnostic power is significantly lower with addition of p-taurel
  4. 1–42 amyloid-beta of 42 amino acids, AD Alzheimer’s disease, CJD Creutzfeldt-Jakob disease, CSF cerebrospinal fluid, DLB dementia with Lewy bodies, FTLD frontotemporal lobar degeneration, p-tau 181 tau protein phosphorylated at threonine 181, p-tau rel non-phosphorylated tau fraction, t-tau total tau protein